JP2023553354A - アルファ－７ニコチン性アセチルコリン受容体アゴニストを用いた、スピーチ不安の治療 - Google Patents

アルファ－７ニコチン性アセチルコリン受容体アゴニストを用いた、スピーチ不安の治療 Download PDF

Info

Publication number
JP2023553354A
JP2023553354A JP2023532250A JP2023532250A JP2023553354A JP 2023553354 A JP2023553354 A JP 2023553354A JP 2023532250 A JP2023532250 A JP 2023532250A JP 2023532250 A JP2023532250 A JP 2023532250A JP 2023553354 A JP2023553354 A JP 2023553354A
Authority
JP
Japan
Prior art keywords
sad
subject
compound
fear
anxiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023532250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553354A5 (https=
Inventor
ポリメロポウロス、ミハエル
ホー、ユンション
ポリメロポウロス、クリストス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of JP2023553354A publication Critical patent/JP2023553354A/ja
Publication of JP2023553354A5 publication Critical patent/JP2023553354A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2023532250A 2020-11-25 2021-11-24 アルファ－７ニコチン性アセチルコリン受容体アゴニストを用いた、スピーチ不安の治療 Pending JP2023553354A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063118121P 2020-11-25 2020-11-25
US202063118132P 2020-11-25 2020-11-25
US63/118,132 2020-11-25
US63/118,121 2020-11-25
US202163158449P 2021-03-09 2021-03-09
US63/158,449 2021-03-09
PCT/US2021/060720 WO2022115526A1 (en) 2020-11-25 2021-11-24 Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist

Publications (2)

Publication Number Publication Date
JP2023553354A true JP2023553354A (ja) 2023-12-21
JP2023553354A5 JP2023553354A5 (https=) 2024-12-03

Family

ID=78957498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532250A Pending JP2023553354A (ja) 2020-11-25 2021-11-24 アルファ－７ニコチン性アセチルコリン受容体アゴニストを用いた、スピーチ不安の治療

Country Status (8)

Country Link
US (1) US20230381169A1 (https=)
EP (1) EP4251158A1 (https=)
JP (1) JP2023553354A (https=)
KR (1) KR20230112622A (https=)
AU (1) AU2021387993A1 (https=)
CA (1) CA3199760A1 (https=)
MX (1) MX2023005895A (https=)
WO (1) WO2022115526A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005539057A (ja) * 2002-09-04 2005-12-22 ノバルティス アクチエンゲゼルシャフト アザビシクロアルキルエーテルおよびそのα７−ＮＡＣＨＲアゴニストとしての使用
EP2742940A1 (en) * 2012-12-13 2014-06-18 IP Gesellschaft für Management mbH Salts of aza-bicyclo-di-aryl ethers for adminstration once daily, twice daily or thrice daily

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
JP6263469B2 (ja) 2011-07-15 2018-01-17 ノバルティス アーゲー アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005539057A (ja) * 2002-09-04 2005-12-22 ノバルティス アクチエンゲゼルシャフト アザビシクロアルキルエーテルおよびそのα７−ＮＡＣＨＲアゴニストとしての使用
EP2742940A1 (en) * 2012-12-13 2014-06-18 IP Gesellschaft für Management mbH Salts of aza-bicyclo-di-aryl ethers for adminstration once daily, twice daily or thrice daily

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
笠原敏彦: ""Social Phobiaは社交恐怖か?"", 精神神経学雑誌, vol. 112(7), JPN6025053597, 2010, pages 644 - 649, ISSN: 0005765698 *

Also Published As

Publication number Publication date
AU2021387993A9 (en) 2024-02-08
CA3199760A1 (en) 2022-06-02
AU2021387993A1 (en) 2023-06-08
US20230381169A1 (en) 2023-11-30
EP4251158A1 (en) 2023-10-04
KR20230112622A (ko) 2023-07-27
WO2022115526A1 (en) 2022-06-02
MX2023005895A (es) 2023-06-06

Similar Documents

Publication Publication Date Title
JP2025036702A (ja) 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
JP5792061B2 (ja) 神経及び精神障害の治療法
US11826321B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
JP2025510294A (ja) 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
AU2023244452A1 (en) Treatment of cognitive dysfunction
CN102046174A (zh) 针对氨基吡啶的延长的疗法的组合物和方法
US20240299375A1 (en) Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
JP2022514659A (ja) ドーパミン作動性ｃｎｓ障害の治療におけるｌｙ３１５４２０７の使用のための用量レジメン
MX2014003997A (es) Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas.
JP2023521492A (ja) ダリドレキサントの医学的用途
JP2023553354A (ja) アルファ－７ニコチン性アセチルコリン受容体アゴニストを用いた、スピーチ不安の治療
RU2840314C1 (ru) Лечение боязни публичного выступления агонистом альфа-7 никотинового ацетилхолинового рецептора
CN116761604A (zh) 用α-7烟碱型乙酰胆碱受体激动剂治疗当众讲话焦虑
US20240197698A1 (en) Treatment of acute anxiety with an alpha-7 nicotinic acetylcholine receptor modulator
US20240358693A1 (en) Methods of treating pain
HK40112834A (zh) 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
JP2025069218A (ja) 神経変性疾患における転倒および転倒頻度に関連する処置のための組成物および方法
JP2023520016A (ja) 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
HK40068315A (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
HK40032890A (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
JP2018127497A (ja) アミノピリジンを使用した、ある種の卒中に関連した感覚運動障害を治療するための方法
HK1157591A (en) Compositions and methods for extended therapy with aminopyridines
HK1184674B (en) Treatment for neurological and mental disorders
WO2012048871A1 (en) Memantine for improving cognitive performance in subjects

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260325